Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Immune‐modifying monoclonal antibodies may induce or enhance the natural immune response against tumor cells. The complex interaction between antigen‐presenting cells and T lymphocytes as an immune response is strongly affected by anti‐CD152 (CTLA‐4)‐antibodies. The cytotoxic T‐lymphocyte (CTLA‐4) receptor binds molecules of the B7‐family which leads to a suppression of T cells. Specific CTLA‐4 antibodies induce an unrestrained T‐cell activation. Treatment with the CTLA‐4 antibodies ipilimumab and tremelimumab has been investigated in metastatic melanoma only within clinical trials. Currently, the critical phase III trial on ipilimumab is in the final analysis process and expected to lead to approval. CTLA‐4 antibodies belong to the most promising new molecules for the treatment of advanced melanoma. During treatment with CTLA‐4 antibodies, distinct adverse events may occur. Treating physicians must be familiar with their appropriate treatment and prophylaxis. The most frequently observed side effects are diseases such as an autoimmune colitis which is typically characterized by a mild to moderate, but occasionally also severe and persistent diarrhea. Other autoimmune‐mediated side effects like hypophysitis, hepatitis, iridocyclitis or an exacerbation of lupus nephritis have been reported in the literature. Their early recognition and treatment are mandatory to reduce the risk of sequelae for CTLA‐4‐antibod‐treated patients. Autoimmune‐mediated side effects are reported to correlate positively with treatment response. We review the mechanisms of action, provide an update on clinical trials with the two CTLA‐4‐antibodies for metastatic melanoma, and present detailed recommendations for managing the side effects of these new agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135
Lutzky, J., Wolchok, J., Hamid, O., Lebbe, C., Pehamberger, H., Linette, G., de Pril, V., Ibrahim, R., Hoos, A., & O'Day, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9034 · Cited by 58
Cited by
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1916 · Cited by 449
Weber, J. S., Dummer, R., de Pril, V., Lebbé, C., Hodi, F. S., & for the MDX010‐20 Investigators (2013) · Cancer · doi:10.1002/cncr.27969 · Cited by 447
Eigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grünwald, V., Kähler, K. C., Loquai, C., Reinmuth, N., Steins, M., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.003 · Cited by 406
Self-citationIpilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320
Potential biomedical applications of marine algae
Wang, H.-M. D., Li, X.-C., Lee, D.-J., & Chang, J.-S. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2017.05.198 · Cited by 217
Metadata
- Authors
- Kähler, K. C., & Hauschild, A.
- Venue
- JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Publisher
- Wiley
- Published
- 2010-11-17
- Volume
- 9
- Issue
- 4
- Pages
- 277-286
- ISSN
- 1610-0379 (ISSN-L)
- 1610-0387
- OpenAlex
- W1529517822
- Cited by
- 108
- References
- 7
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma. https://app.cochat.ai/papers/10.1111/j.1610-0387.2010.07568.x
- The paper
- Kähler, K. C., & Hauschild, A. (2011). Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/j.1610-0387.2010.07568.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.